# Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy

> **NCT01405950** · PHASE1 · TERMINATED · sponsor: **Acorda Therapeutics** · enrollment: 10 (actual)

## Conditions studied

- Spasticity Due to Cerebral Palsy

## Interventions

- **DRUG:** Zanaflex Capsules
- **DRUG:** Zanaflex Capsules
- **DRUG:** Zanaflex Capsules
- **DRUG:** Zanaflex Capsules

## Key facts

- **NCT ID:** NCT01405950
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Please see 'Further study details as provided by Acorda Therapeutics' for explanation of why study stopped.
- **Last updated:** 2013-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01405950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01405950, "Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01405950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*